Compare PCRX & DJCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCRX | DJCO |
|---|---|---|
| Founded | 2006 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Newspapers/Magazines |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 706.2M |
| IPO Year | 2010 | 1995 |
| Metric | PCRX | DJCO |
|---|---|---|
| Price | $22.00 | $508.47 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $35.33 | N/A |
| AVG Volume (30 Days) | ★ 739.7K | 84.6K |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 107.44 | 43.50 |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $541,533,000.00 | $41,384,000.00 |
| Revenue This Year | $9.77 | N/A |
| Revenue Next Year | $9.71 | N/A |
| P/E Ratio | $142.97 | ★ N/A |
| Revenue Growth | ★ 26.04 | N/A |
| 52 Week Low | $18.80 | $348.63 |
| 52 Week High | $27.99 | $674.75 |
| Indicator | PCRX | DJCO |
|---|---|---|
| Relative Strength Index (RSI) | 47.57 | 43.72 |
| Support Level | $20.41 | $383.43 |
| Resistance Level | $23.82 | $674.75 |
| Average True Range (ATR) | 1.00 | 37.11 |
| MACD | -0.00 | 1.27 |
| Stochastic Oscillator | 43.41 | 52.66 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Daily Journal Corp publishes newspapers and websites covering California and Arizona and produces several specialized information services. The company operates in two segments: Traditional business and Journal Technologies which includes Journal Technologies, Inc. and Journal Technologies (Canada) Inc. It also serves as a newspaper representative specializing in public notice advertising. The majority of revenue is generated from the Traditional segment.